A confirmatory phase III trial, CodeBreaK 200, was launched in 148 centers in 22 countries to evaluate sotorasib versus standard of care docetaxel in second-line KRAS G12C-mutant NSCLC with prior exposure to a platinum agent and an immune checkpoint inhibitor. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.